[1]
K. Sarwar, “PHARMACOECONOMIC CONSIDERATIONS AND QUALITY OF LIFE ASSESSMENT IN HEPATITIS C PATIENTS”, Pak J Public Health, vol. 9, no. 3, pp. 149–152, Mar. 2020, doi: 10.32413/pjph.v9i3.394.